149 related articles for article (PubMed ID: 2282421)
1. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years.
Jolley AG; Hirsch SR; Morrison E; McRink A; Wilson L
BMJ; 1990 Oct; 301(6756):837-42. PubMed ID: 2282421
[TBL] [Abstract][Full Text] [Related]
2. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.
Jolley AG; Hirsch SR; McRink A; Manchanda R
BMJ; 1989 Apr; 298(6679):985-90. PubMed ID: 2567190
[TBL] [Abstract][Full Text] [Related]
3. [Prodromal symptoms in schizophrenic relapse: A descriptive and comparative study].
Bouhlel S; Jones Y; Khelifa E; Msolly M; Melki W; El-Hechmi Z
Encephale; 2012 Oct; 38(5):397-403. PubMed ID: 23062453
[TBL] [Abstract][Full Text] [Related]
4. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Eklund K; Forsman A
Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
[TBL] [Abstract][Full Text] [Related]
5. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
Youssef HA
Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole: new drug. Just another neuroleptic.
Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
[TBL] [Abstract][Full Text] [Related]
7. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
8. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
9. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.
Marder SR; Glynn SM; Wirshing WC; Wirshing DA; Ross D; Widmark C; Mintz J; Liberman RP; Blair KE
Am J Psychiatry; 2003 Aug; 160(8):1405-12. PubMed ID: 12900301
[TBL] [Abstract][Full Text] [Related]
10. [Detection of early warning signs in schizophrenic patients. Possible applications in prevention of recurrence].
Wiedemann G; Hahlweg K; Hank G; Feinstein E; Müller U; Dose M
Nervenarzt; 1994 Jul; 65(7):438-43. PubMed ID: 7800087
[TBL] [Abstract][Full Text] [Related]
11. Risperidone in treatment-refractory schizophrenia.
Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
[TBL] [Abstract][Full Text] [Related]
12. Intermittent vs maintenance medication in schizophrenia. Two-year results.
Herz MI; Glazer WM; Mostert MA; Sheard MA; Szymanski HV; Hafez H; Mirza M; Vana J
Arch Gen Psychiatry; 1991 Apr; 48(4):333-9. PubMed ID: 1672588
[TBL] [Abstract][Full Text] [Related]
13. Overview: efficacy and safety of the rapid neuroleptization method with injectable haloperidol.
Donlon PT; Hopkin J; Tupin JP
Am J Psychiatry; 1979 Mar; 136(3):273-8. PubMed ID: 369395
[TBL] [Abstract][Full Text] [Related]
14. [Relapse in schizophrenia: an exploratory study of the joint conceptions of patients, parents and caregivers].
Koenig M; Castillo MC; Urdapilleta I; Le Borgne P; Bouleau JH
Encephale; 2011 Jun; 37(3):207-16. PubMed ID: 21703436
[TBL] [Abstract][Full Text] [Related]
15. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.
Chatterjee A; Chakos M; Koreen A; Geisler S; Sheitman B; Woerner M; Kane JM; Alvir J; Lieberman JA
Am J Psychiatry; 1995 Dec; 152(12):1724-9. PubMed ID: 8526237
[TBL] [Abstract][Full Text] [Related]
17. Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment?
Gaebel W
Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 5():11-6. PubMed ID: 7622828
[TBL] [Abstract][Full Text] [Related]
18. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Csernansky JG; Mahmoud R; Brenner R;
N Engl J Med; 2002 Jan; 346(1):16-22. PubMed ID: 11777998
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W
Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
